Search results
1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as sodium monohydrate). Excipients with known effect: Contains 154.6 mg anhydrous lactose (equivalent to 162.75 mg lactose monohydrate).
EU/1/03/265/006. Bonviva Bonviva Bonviva. Bonviva 150 mg 150 mg. 3 mg. 3 mg Film-coated tablet Film-coated tablet Solution for injection. Solution for injection Oral use Oral use Intravenous. Intravenous. 1/1.
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as ibandronic sodium monohydrate). Excipients: Contains 162.75 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3.
Bonviva is a medicine that contains the active substance ibandronic acid. It is available as tablets (150 mg) and as a solution for injection in a prefilled syringe (3 mg).
Bonviva 150 mg is indicated for the prevention of osteoporosis in postmenopausal women who are not yet osteoporotic, but are at increased risk for fractures as defined in the current national Clinical Guidelines
Bonviva is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures. Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause. At the menopause, a woman’s ovaries stop producing the female hormone, oestrogen, which helps to keep her skeleton healthy.
Bonviva 3 mg every 3 months i.v. is in patients 2.4 Warnings and Precautions 2.4.1 General Bonviva other bisphosphonates y may cause a in serum other of bone be ef before starting Bonviva injection therapy. intake of vitamin D is important in patients. Patients must receive vitamin D. Bonviva 3 mg every 3 months i.v. is not for use in patients ...
